Philip Vickers
Director/Board Member at AVROBIO, INC.
Net worth: 6 144 $ as of 2024-03-30
Profile
Philip J.
Vickers is currently the President & Chief Executive Officer at Solu Therapeutics, Inc. He is also an Independent Director at Avrobio, Inc. and a Director at Northern Mosaic LP.
Previously, he held positions such as President, Chief Executive Officer & Director at Northern Biologics, Inc. from 2017 to 2020, President, Chief Executive Officer & Director at Faze Medicines, Inc. from 2021 to 2022, President, Director & Chief Scientific Officer at Resolvyx Pharmaceuticals, Inc. from 2009 to 2011, and Global Head-Research & Development at Shire Plc from 2013 to 2017.
He has also served as an Independent Director at Revance Therapeutics, Inc. from 2015 to 2023.
Additionally, he has held positions at Neusentis Ltd., Boehringer Ingelheim Corp., Pfizer (St. Louis), and Merck Research Laboratories Massachusetts LLC.
Dr. Vickers completed his undergraduate degree at the University of Salford and obtained a doctorate degree from the University of Toronto.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
AVROBIO INC
0.01% | 2023-06-05 | 4,800 ( 0.01% ) | 6 144 $ | 2024-03-30 |
Philip Vickers active positions
Companies | Position | Start |
---|---|---|
AVROBIO, INC. | Director/Board Member | 2019-01-06 |
Northern Mosaic LP
Northern Mosaic LP Miscellaneous Commercial ServicesCommercial Services Northern Mosaic LP provides biotechnology technology services. The company is headquartered in Toronto, Canada. | Director/Board Member | - |
Solu Therapeutics
Solu Therapeutics Pharmaceuticals: MajorHealth Technology Solu Therapeutics is an American precision-medicine company focused on developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The company is located in the US. The company's proprietary cytotoxicity targeting chimera (cytac) platform and drug candidates, licensed from GSK, unlock antibody-intractable cell surface targets, providing the capability to develop next-generation medicines that harness the power of biologics with the vast target binding space of small molecules. | Chief Executive Officer | - |
Former positions of Philip Vickers
Companies | Position | End |
---|---|---|
REVANCE THERAPEUTICS, INC. | Director/Board Member | 2023-05-02 |
Faze Medicines, Inc. /MA)
Faze Medicines, Inc. /MA) Miscellaneous Commercial ServicesCommercial Services Faze Medicines, Inc. provides medical services. The company is headquartered in San Francisco, CA. | Chief Executive Officer | 2022-10-31 |
Northern Biologics, Inc.
Northern Biologics, Inc. Hospital/Nursing ManagementHealth Services Northern Biologics Inc. operates as an early-stage biologics company. It develops a portfolio of antibody-based therapeutics for oncology and fibrosis. The company was founded by Jason Moffat, Rob Rottapel, Benjamin G. Neel, Sachdev Sidhu, Brad Wouters, and Stefan Larson in June 2014 and is headquartered in Toronto, Canada. | Chief Executive Officer | 2020-11-30 |
SHIRE | Chief Tech/Sci/R&D Officer | 2017-05-31 |
Resolvyx Pharmaceuticals, Inc.
Resolvyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Resolvyx Pharmaceuticals, Inc. discovers and develops therapeutics for inflammatory diseases. Its products include RX-10001, RX-10045 and RX-20001. The firm's focus is to develop a new class of medicines called Resolvins for the treatment of a range of ophthalmic diseases. The company was founded by Daniel Goodman, Charles N. Serhan, Per Gjorstrup and Thomas E. Van Dyke in June 20, 2001 and is headquartered in Cambridge, MA. | President | 2010-12-31 |
Training of Philip Vickers
University of Salford | Undergraduate Degree |
University of Toronto | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
REVANCE THERAPEUTICS, INC. | Health Technology |
AVROBIO, INC. | Health Technology |
Private companies | 10 |
---|---|
Resolvyx Pharmaceuticals, Inc.
Resolvyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Resolvyx Pharmaceuticals, Inc. discovers and develops therapeutics for inflammatory diseases. Its products include RX-10001, RX-10045 and RX-20001. The firm's focus is to develop a new class of medicines called Resolvins for the treatment of a range of ophthalmic diseases. The company was founded by Daniel Goodman, Charles N. Serhan, Per Gjorstrup and Thomas E. Van Dyke in June 20, 2001 and is headquartered in Cambridge, MA. | Health Technology |
Shire Plc
Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
Boehringer Ingelheim Corp.
Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT. | Health Technology |
Pfizer (St. Louis)
Pfizer (St. Louis) BiotechnologyHealth Technology Part of Pfizer Inc., Pfizer (St. Louis) is a private company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO. | Health Technology |
Merck Research Laboratories Massachusetts LLC
Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Research Laboratories Massachusetts LLC is a pharmaceutical company that provides free medicines and adult vaccines to qualified patients through their Merck Patient Assistance Program. The private company is based in Boston, MA and is a part of Merck & Co., Inc. and its affiliates. The company also offers information about insurance coverage and financial assistance options for eligible patients. The company conducts clinical trials and provides medical information covering thousands of topics in all fields of medicine through their Merck Manuals. Additionally, they report on their commitment to operating responsibly to benefit society through their corporate responsibility program, which includes their environmental, social, and governance (ESG) report. Merck for Mothers is an initiative to create a world where no woman has to die giving life. | Health Technology |
Neusentis Ltd.
Neusentis Ltd. Miscellaneous Commercial ServicesCommercial Services Neusentis Ltd. engages in other business support service activities. The company was founded on October 2, 1997 and is headquartered in Sandwich, the United Kingdom. | Commercial Services |
Northern Biologics, Inc.
Northern Biologics, Inc. Hospital/Nursing ManagementHealth Services Northern Biologics Inc. operates as an early-stage biologics company. It develops a portfolio of antibody-based therapeutics for oncology and fibrosis. The company was founded by Jason Moffat, Rob Rottapel, Benjamin G. Neel, Sachdev Sidhu, Brad Wouters, and Stefan Larson in June 2014 and is headquartered in Toronto, Canada. | Health Services |
Northern Mosaic LP
Northern Mosaic LP Miscellaneous Commercial ServicesCommercial Services Northern Mosaic LP provides biotechnology technology services. The company is headquartered in Toronto, Canada. | Commercial Services |
Faze Medicines, Inc. /MA)
Faze Medicines, Inc. /MA) Miscellaneous Commercial ServicesCommercial Services Faze Medicines, Inc. provides medical services. The company is headquartered in San Francisco, CA. | Commercial Services |
Solu Therapeutics
Solu Therapeutics Pharmaceuticals: MajorHealth Technology Solu Therapeutics is an American precision-medicine company focused on developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The company is located in the US. The company's proprietary cytotoxicity targeting chimera (cytac) platform and drug candidates, licensed from GSK, unlock antibody-intractable cell surface targets, providing the capability to develop next-generation medicines that harness the power of biologics with the vast target binding space of small molecules. | Health Technology |
- Stock Market
- Insiders
- Philip Vickers